Oral Estradiol and Sexual Function: What the Evidence Actually Shows

What does oral estradiol do for sexual function?

Estradiol is the principal intracellular human estrogen and is substantially more potent at the receptor than its metabolites estrone and estriol [1]. The sexual complaint the tablet is labeled for is vulvar and vaginal atrophy, the postmenopausal tissue change that can cause dryness, discomfort and painful intercourse [1][6]. Low desire is not a labeled indication.

Does oral estradiol relieve vaginal dryness and pain with sex?

It is an approved treatment for the tissue problem. When oral estradiol is prescribed solely for the treatment of symptoms of vulvar and vaginal atrophy, the oral label says topical vaginal products should be considered [1]. The Climara patch label says to first consider topical vaginal products in the same situation [4].

Oral estradiol is also labeled for moderate to severe menopausal hot flashes. For osteoporosis prevention, the label limits its use to women at significant risk of osteoporosis for whom non-estrogen medications are not considered appropriate [1].

These symptoms are common and often unrecognized. In the VIVA survey of 3,520 postmenopausal women aged 55 to 65 in seven countries, 45% reported vaginal symptoms, only 4% attributed them to vaginal atrophy, 63% did not recognize atrophy as a chronic condition, and 75% said it had a negative impact on their life; 46% said they lacked knowledge about local estrogen therapy [7].

A 2016 Cochrane review pooled randomized comparisons of vaginal estrogen preparations (creams, pessaries, tablets and the estradiol-releasing ring) used for at least 12 weeks for vaginal atrophy, with participant-rated symptom improvement and endometrial thickness as the primary outcomes [6]. It covered intravaginal products only and does not tell us how oral estradiol compares with them.

Does it improve desire?

The most careful statement available is broad rather than tablet-specific. A 2009 review of estrogen and women's sexual function concluded that systemic estrogen treatments are associated with significant benefits in some domains of menopausal sexual function, especially when estradiol is delivered transdermally, whereas local estrogens are effective in preventing urogenital aging [2]. That is a review conclusion, not a trial of the oral tablet.

Berman and colleagues evaluated 48 women who complained of sexual dysfunction using physiologic measurements: genital blood peak systolic velocity, vaginal pH, vaginal pressure-volume changes and vibratory perception thresholds, recorded before and after sexual stimulation. Women aged 55 to 71 and menopausal women not using hormone replacement had significantly lower physiologic responses. In the same group, difficulty reaching orgasm was reported by 92%, low arousal by 67%, pain during or after intercourse by 67%, and low desire by 21% [8]. The study measured physiology in a clinic sample, not the effect of starting oral estradiol.

The randomized evidence for desire belongs to testosterone. A 2019 systematic review and meta-analysis of 36 randomized trials with 8,480 participants found that testosterone, compared with placebo or with a comparator such as estrogen with or without a progestogen, improved sexual desire in postmenopausal women (standardized mean difference 0.36, 95% CI 0.22 to 0.50), arousal (0.28, 0.21 to 0.35), orgasm (0.25, 0.18 to 0.32) and satisfactory sexual event frequency (mean difference 0.85, 95% CI 0.52 to 1.18) [3]. Oral testosterone raised LDL cholesterol in that analysis, while non-oral forms did not [3].

The 2021 ISSWSH guideline recommends systemic transdermal testosterone for women with hypoactive sexual desire disorder not primarily related to modifiable factors such as relationship or mental health problems. It describes the benefit as moderate, notes that the use is off-label with long-term safety not established, and states that a total testosterone level should not be used to diagnose low desire, only as a baseline for monitoring [9].

Does the route matter, oral versus transdermal?

The Climara label states that systemic availability of estradiol after transdermal use is about 20 times higher than after oral use because there is no first-pass metabolism [4].

On outcomes, the 2009 review reported that the sexual-function benefits of systemic estrogen were seen especially with transdermal estradiol [2]. It is a literature review, not a head-to-head trial of the two routes.

What safety information applies?

The oral estradiol label says unopposed estrogen raises endometrial cancer risk in a woman with a uterus, with a reported risk about 2- to 12-fold greater than in non-users and 15- to 24-fold for five to ten years or more of use; adding a progestin reduces the risk of endometrial hyperplasia. It says a progestin should also be started in a postmenopausal woman with a uterus, and that a woman without a uterus does not need one [1]. Among its contraindications, the oral label lists breast cancer or a history of breast cancer (except in appropriately selected patients with metastatic disease), active deep vein thrombosis or pulmonary embolism or a history of those conditions, and active or recent arterial thromboembolic disease such as stroke or myocardial infarction [1]. The Climara patch label also lists protein C, protein S or antithrombin deficiency and other known thrombophilic disorders [4].

Clot risk depends heavily on route in the observational data. In ESTHER, a French case-control study of 271 women with a first idiopathic venous thromboembolism and 610 matched controls, current oral estrogen use had an adjusted odds ratio of 4.2 (95% CI 1.5 to 11.6) versus non-use, and transdermal use was 0.9 (0.4 to 2.1) [5]. A BMJ meta-analysis of eight observational studies and nine randomized trials found pooled observational odds ratios of 2.5 (1.9 to 3.4) for oral estrogen and 1.2 (0.9 to 1.7) for transdermal, with oral risk highest in the first year at 4.0 (2.9 to 5.7) [10]. The route comparisons are observational rather than randomized, and the labels still carry clot warnings and contraindications.

The boxed-warning language cites Women's Health Initiative trials of oral conjugated equine estrogens 0.625 mg, alone or with medroxyprogesterone 2.5 mg, not trials of estradiol [11][12]. On labeling status, FDA asked makers of menopausal hormone therapy in November 2025 to remove boxed-warning language on cardiovascular disease, breast cancer and probable dementia, while keeping the endometrial cancer boxed warning on systemic estrogen-alone products [13]. On 12 February 2026 FDA announced the first six products with approved changes, and oral estradiol tablets are not on that list [14][15]. The current DailyMed oral estradiol tablet label (Teva) still carries the older, longer boxed warning [1].

Dose and follow-up in the label

The label's usual initial dose for menopausal symptoms is 1 to 2 mg of estradiol daily, adjusted to control symptoms, with cyclic administration, for example three weeks on and one week off [1]. The label says patients should be reevaluated at 3 to 6 month intervals and that attempts to taper or stop should be made at 3 to 6 month intervals. It also says estrogens should, if feasible, be discontinued at least 4 to 6 weeks before surgery associated with increased clot risk or during prolonged immobilization [1].